NO319827B1 - Anvendelse av kolesterolsenkende middel og fremgangsmate for fremstilling derav, samt farmasoytisk sammensetning - Google Patents

Anvendelse av kolesterolsenkende middel og fremgangsmate for fremstilling derav, samt farmasoytisk sammensetning Download PDF

Info

Publication number
NO319827B1
NO319827B1 NO20013810A NO20013810A NO319827B1 NO 319827 B1 NO319827 B1 NO 319827B1 NO 20013810 A NO20013810 A NO 20013810A NO 20013810 A NO20013810 A NO 20013810A NO 319827 B1 NO319827 B1 NO 319827B1
Authority
NO
Norway
Prior art keywords
levels
compound
pharmaceutically acceptable
acceptable salt
preparation
Prior art date
Application number
NO20013810A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013810D0 (no
NO20013810L (no
Inventor
Ali Raza
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO319827(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902590.0A external-priority patent/GB9902590D0/en
Priority claimed from GBGB9921062.7A external-priority patent/GB9921062D0/en
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20013810D0 publication Critical patent/NO20013810D0/no
Publication of NO20013810L publication Critical patent/NO20013810L/no
Publication of NO319827B1 publication Critical patent/NO319827B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20013810A 1999-02-06 2001-08-03 Anvendelse av kolesterolsenkende middel og fremgangsmate for fremstilling derav, samt farmasoytisk sammensetning NO319827B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9902590.0A GB9902590D0 (en) 1999-02-06 1999-02-06 Use of cholesterol-lowering agent
GBGB9921062.7A GB9921062D0 (en) 1999-09-08 1999-09-08 Use of cholestrol-lowering agent
PCT/GB2000/000285 WO2000045819A1 (en) 1999-02-06 2000-02-01 Use of cholesterol-lowering agent

Publications (3)

Publication Number Publication Date
NO20013810D0 NO20013810D0 (no) 2001-08-03
NO20013810L NO20013810L (no) 2001-10-03
NO319827B1 true NO319827B1 (no) 2005-09-19

Family

ID=26315084

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013810A NO319827B1 (no) 1999-02-06 2001-08-03 Anvendelse av kolesterolsenkende middel og fremgangsmate for fremstilling derav, samt farmasoytisk sammensetning

Country Status (22)

Country Link
EP (1) EP1150679A1 (enExample)
JP (2) JP2002536333A (enExample)
KR (1) KR100699287B1 (enExample)
CN (1) CN1347320A (enExample)
AR (1) AR022462A1 (enExample)
AU (1) AU769897B2 (enExample)
BR (1) BR0007991A (enExample)
CA (1) CA2358641A1 (enExample)
CZ (1) CZ20012631A3 (enExample)
EE (1) EE04659B1 (enExample)
HK (1) HK1040924A1 (enExample)
HU (1) HUP0105019A3 (enExample)
ID (1) ID30131A (enExample)
IL (1) IL144662A0 (enExample)
IS (1) IS5996A (enExample)
MY (1) MY136382A (enExample)
NO (1) NO319827B1 (enExample)
NZ (1) NZ512681A (enExample)
PL (1) PL349137A1 (enExample)
SK (1) SK11112001A3 (enExample)
TR (1) TR200102236T2 (enExample)
WO (1) WO2000045819A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
SE0103509D0 (sv) * 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2007142581A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Combination product for the treatment or prevention of dyslipidaemia
US8436028B2 (en) 2007-06-20 2013-05-07 Merck Sharp & Dohme Corp CETP inhibitors derived from benzoxazole arylamides
US8445480B2 (en) 2007-06-20 2013-05-21 Merck Sharp & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
EP2166847B1 (en) * 2007-06-20 2014-11-19 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
EP2216095A1 (en) * 2009-01-27 2010-08-11 Koninklijke Philips Electronics N.V. Microfluidic device for full blood count

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260446A (en) * 1989-12-22 1993-11-09 Basf Aktiengesellschaft Aminothiazoles
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体

Also Published As

Publication number Publication date
NZ512681A (en) 2003-12-19
AU769897B2 (en) 2004-02-05
EE04659B1 (et) 2006-08-15
CN1347320A (zh) 2002-05-01
HUP0105019A3 (en) 2003-02-28
IS5996A (is) 2001-07-10
WO2000045819A1 (en) 2000-08-10
KR100699287B1 (ko) 2007-03-26
BR0007991A (pt) 2001-11-06
AR022462A1 (es) 2002-09-04
NO20013810D0 (no) 2001-08-03
NO20013810L (no) 2001-10-03
EE200100404A (et) 2002-10-15
TR200102236T2 (tr) 2001-12-21
KR20010089631A (ko) 2001-10-06
JP2011137023A (ja) 2011-07-14
CA2358641A1 (en) 2000-08-10
AU2305100A (en) 2000-08-25
EP1150679A1 (en) 2001-11-07
IL144662A0 (en) 2002-05-23
SK11112001A3 (sk) 2002-02-05
JP2002536333A (ja) 2002-10-29
PL349137A1 (en) 2002-07-01
MY136382A (en) 2008-09-30
ID30131A (id) 2001-11-08
CZ20012631A3 (cs) 2001-10-17
HK1040924A1 (zh) 2002-06-28
HUP0105019A2 (hu) 2002-05-29

Similar Documents

Publication Publication Date Title
US6369103B1 (en) Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor
KR100815042B1 (ko) 이형접합성 가족성 고콜레스테롤혈증 치료에 있어서로수바스타틴(ｚｄ－４５２２)의 용도
KR100449604B1 (ko) 지질농도를 조절하는 제약 조성물 및 방법
JP2011137023A (ja) コレステロール低下薬の使用
AU2002214165A1 (en) Use of rosuvastatin (ZD-4522) in the treatment of heterozygous familial hypercholesterolemia
US20140121229A1 (en) Combination comprising s-[2-([[1-(2-ethylbutyl)cyclohexyl] carbonyl]amino)phenyl] 2-methylpropanethioate and an hmg coa reductase inhibitor
JP2007503381A (ja) メトホルミンとスタチンとの組み合わせを含む医薬組成物
KR20050110017A (ko) Ｓ-'２-(''１-(２-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-２-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
EA002435B1 (ru) Способ снижения уровня липопротеина (а) в сыворотке или в плазме крови млекопитающих
MXPA06006831A (es) Uso de estatinas para el tratamiento del sindrome metabolico.
MXPA01007294A (es) Uso de un agente que reduce colesterol
EA018442B1 (ru) Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом
DK169304B1 (da) Anvendelse af ponalrestat til fremstilling af et urinsyresænkende lægemiddel
US20050182036A1 (en) Medicinal composition containing an HMG-CoA reductase inhibitor
US20150164875A1 (en) Compound Preparation of Lercanidipine and Atorvastatin
EP1621210A1 (en) Adiponectin production enhancer
WO2025168652A1 (en) Azd-0780 in combination with a statin for use in lowering ldl-c levels and treating cardiovacular diseases
Gnasso et al. Simvastatin in the treatment of patients with hypercholesterolemia and associated coronary heart disease risk factors: An Italian multicenter study
CA2233748A1 (en) Medicine
JP2013526499A (ja) キサンチンオキシダーゼ阻害剤およびスタチンの合剤およびその使用
HK40058705A (en) Methods of reducing the risk of cardiovascular events in a subject
Athyros et al. Effect of pravastatin in the prevention of coronary heart disease in patients with primary hypercholesterolemia
Patel et al. and Lipid Disorders
HK1051325A1 (en) New combination of a betablocker and a cholesterol-lowering agent

Legal Events

Date Code Title Description
REER Request for administrative reevaluation of patent

Filing date: 20151218

Opponent name: ACTAVIS GROUP PTC EHF

PDP Decision of opposition (par. 25 patent act)

Free format text: PATENT NR. 319827 OPPHEVES

Opponent name: RUBB INTERNATIONAL AS, NO

Effective date: 20091026